Tryp Therapeutics (CNSX: TRYP) announced having filed for a provisional patent for improved administration of Psychedelics. The patent describes the improved methods for formulation, delivery and dosing of psychedelics.
The filing captures various things including the method for producing the active pharmaceutical ingredient, procedures to increase the safety profile of treatments, measures used to minimize the risk of abuse and addiction and novel formulations.
The company claims these technologies are likely to help in reducing time spent on disocciative stage.
Jim Gilligan who doubles up as Tyrp’s President and Chief Science Officer said they are using the patent to differentiate their position in psychedelics depending on how they formulate, deliver and dose their products.
“We are seizing the opportunity to further differentiate our intellectual property position in psychedelics through core improvements to the formulating, delivery, and dosing of active ingredients,” said Gillian.